Companies Celldex Therapeutics, Inc.
Celldex Therapeutics (CLDX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Celldex Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers20th pct.Of 20 peer CEOs
CEO pay, last three years
- $8,361,844FY2023
- $9,229,165FY2024
- $5,366,709FY2025
CEO total pay was $5,366,709 in fiscal 2025, down from $9,229,165 in fiscal 2024.
FY2025: salary $785,804 · bonus $534,300 · stock awards $0 · option awards $4,027,590
Executives and directors
Anthony Marucci · CEOElizabeth Crowley · ExecutiveMargo Heath-Chiozzi · SVPSam Martin · CFOTibor Keler · EVPCheryl L. Cohen · Independent DirectorDenice Torres · Independent DirectorGarry A. Neil, M.D · Independent DirectorHarry H. Penner, Jr · Chair of the BoardHerbert J. Conrad · Independent DirectorJames J. Marino · Independent DirectorKeith L. Brownlie · Independent DirectorRita I. Jain, M.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Celldex Therapeutics, Inc. in fiscal 2025?
As disclosed, Anthony Marucci (President, Chief Executive Officer and Director) was the highest-paid executive at Celldex Therapeutics, Inc. in fiscal 2025, with total compensation of $5,366,709.
How does Celldex Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Anthony Marucci's total compensation ranked at the 20th percentile of Celldex Therapeutics, Inc.'s disclosed peer group.
What is Celldex Therapeutics, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Celldex Therapeutics, Inc.'s CEO-to-median employee pay ratio was 23:1.
How did shareholders vote on Celldex Therapeutics, Inc.'s executive compensation?
As disclosed, 98.43% of shareholders supported Celldex Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Celldex Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Celldex Therapeutics, Inc. reported total board compensation of $492,904 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Anthony Marucci | $785,804 | $534,300 | $0 | $4,027,590 | $0 | $0 | $19,015 | $5,366,709 |
| President, Chief Executive Officer and Director | ||||||||
| Tibor Keler | 552,699 | 304,366 | 0 | 1,248,553 | 0 | 0 | 10,099 | 2,115,717 |
| Executive Vice President and Chief Scientific Officer | ||||||||
| Elizabeth Crowley | 473,883 | 260,000 | 0 | 1,141,151 | 0 | 0 | 10,175 | 1,885,209 |
| Senior Vice President, Chief Product Development Officer | ||||||||
| Sam Martin | 490,790 | 238,050 | 0 | 1,087,449 | 0 | 0 | 10,823 | 1,827,112 |
| Senior Vice President, Chief Financial Officer and Secretary | ||||||||
| Margo Heath-Chiozzi | 483,900 | 225,450 | 0 | 1,100,875 | 0 | 0 | 10,134 | 1,820,359 |
| Senior Vice President, Regulatory Affairs | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Anthony Marucci | $5,366,709 | $9,229,165 | $8,361,844 | ↓ −3,862,456 |
| Tibor Keler | 2,115,717 | 3,285,978 | 3,420,609 | ↓ −1,170,261 |
| Elizabeth Crowley | 1,885,209 | 2,930,348 | — | ↓ −1,045,139 |
| Sam Martin | 1,827,112 | 2,840,120 | 2,946,626 | ↓ −1,013,008 |
| Margo Heath-Chiozzi | 1,820,359 | 2,859,824 | 2,936,966 | ↓ −1,039,465 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation programs are designed to deliver compensation that allows us to attract and retain superior talent who can perform effectively and succeed in a demanding business environment and that is competitive with our peer group. Our compensation programs are also designed to reward performance against pre-established goals and align the interests of our executives with our stockholders.
| CEO STI target (% of salary) | 65% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Margo Heath-Chiozzi | OPTION | 2025-06-05 | — | — | 82,000 | — | $1,100,875 |
| Anthony Marucci | OPTION | 2025-06-05 | — | — | 300,000 | — | 4,027,590 |
| Tibor Keler | OPTION | 2025-06-05 | — | — | 93,000 | — | 1,248,553 |
| Elizabeth Crowley | OPTION | 2025-06-05 | — | — | 85,000 | — | 1,141,151 |
| Sam Martin | OPTION | 2025-06-05 | — | — | 81,000 | — | 1,087,449 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Margo Heath-Chiozzi | $0 | $0 | $1,100,875 | 0.0% |
| Anthony Marucci | 0 | 0 | 4,027,590 | 0.0% |
| Tibor Keler | 0 | 0 | 1,248,553 | 0.0% |
| Elizabeth Crowley | 0 | 0 | 1,141,151 | 0.0% |
| Sam Martin | 0 | 0 | 1,087,449 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Elizabeth Crowley | Option | 9,625 | 22.48 | — |
| Margo Heath-Chiozzi | Option | 9,625 | 22.48 | — |
| Sam Martin | Option | 10,625 | 22.48 | — |
| Tibor Keler | Option | 11,375 | 22.48 | — |
| Elizabeth Crowley | Option | 30,000 | 36.87 | — |
| Margo Heath-Chiozzi | Option | 30,000 | 36.87 | — |
| Sam Martin | Option | 30,000 | 36.87 | — |
| Anthony Marucci | Option | 31,250 | 22.48 | — |
| Tibor Keler | Option | 34,500 | 36.87 | — |
| Sam Martin | Option | 50,625 | 36.43 | — |
| Margo Heath-Chiozzi | Option | 51,250 | 36.43 | — |
| Elizabeth Crowley | Option | 53,125 | 36.43 | — |
| Tibor Keler | Option | 58,125 | 36.43 | — |
| Sam Martin | Option | 81,000 | 19.53 | — |
| Margo Heath-Chiozzi | Option | 82,000 | 19.53 | — |
| Elizabeth Crowley | Option | 85,000 | 19.53 | — |
| Tibor Keler | Option | 93,000 | 19.53 | — |
| Anthony Marucci | Option | 93,750 | 36.87 | — |
| Anthony Marucci | Option | 187,500 | 36.43 | — |
| Anthony Marucci | Option | 300,000 | 19.53 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Denice TorresIndependent · Compensation and Organization Development · Science and Commercialization · Newly elected | $37,416 | $0 | $443,035 | $0 | $0 | $480,451 |
| Harry H. Penner, JrIndependent · Board Chair | 75,422 | 0 | 221,517 | 0 | 0 | 296,939 |
| James J. MarinoIndependent · Audit · Compensation and Organization Development (Chair) | 72,917 | 0 | 221,517 | 0 | 0 | 294,434 |
| Keith L. BrownlieIndependent · Audit (Chair) | 67,922 | 0 | 221,517 | 0 | 0 | 289,439 |
| Garry A. Neil, M.DIndependent · Audit · Nominating and Corporate Governance | 62,928 | 0 | 221,517 | 0 | 0 | 284,445 |
| Cheryl L. CohenIndependent · Compensation and Organization Development · Science and Commercialization (Chair) | 60,431 | 0 | 221,517 | 0 | 0 | 281,948 |
| Rita I. Jain, M.DIndependent · Nominating and Corporate Governance · Science and Commercialization | 57,934 | 0 | 221,517 | 0 | 0 | 279,451 |
| Herbert J. ConradIndependent · Nominating and Corporate Governance (Chair) | 57,934 | 0 | 221,517 | 0 | 0 | 279,451 |
| Anthony S. MarucciEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $48,000 |
|---|---|
| Annual equity retainer | $221,517 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | 3x annual retainer ($144,000) |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $492,904 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $492,904 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Celldex Therapeutics as a peer
Companies that benchmark against CLDX
16 companies name CLDX as a compensation peer
The list of companies that name CLDX as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ACLX ArcellxKROS Keros TherapeuticsBHVN BiohavenMDGL Madrigal PharmaceuticalsCYTK CytokineticsIBRX ImmunityBioPCVX VaxcyteIMVT ImmunovantARVN ArvinasDNLI Denali TherapeuticsSWTX SpringWorks TherapeuticsAPLS Apellis PharmaceuticalsKNSA Kiniksa PharmaceuticalsSNDX Syndax PharmaceuticalsPTGX Protagonist TherapeuticsROIV Roivant SciencesINBX InhibrxZNTL Zentalis PharmaceuticalsBBIO BridgeBio PharmaCRSP CRISPR Therapeutics
Peer reciprocity
The companies Celldex Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Keros Therapeutics (KROS)66Immunovant (IMVT)67Protagonist Therapeutics (PTGX)68Zentalis Pharmaceuticals (ZNTL)69
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Roivant Sciences | 2025 | Eric Venker | $75,000 | $2,261,908 | $0 | $0 | $24,400,210 |
| 2 | Arcellx | 2024 | Rami Elghandour | 653,288 | 9,342,069 | 10,850,151 | 0 | 21,402,668 |
| 3 | Immunovant | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 4 | Madrigal Pharmaceuticals | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 5 | SpringWorks Therapeutics | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 6 | BridgeBio Pharma | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 7 | Vaxcyte | 2025 | Grant Pickering | 800,000 | 4,300,159 | 8,714,048 | 630,000 | 14,458,937 |
| 8 | Biohaven | 2025 | Vlad Coric | 920,400 | 2,202,480 | 9,900,043 | 0 | 13,500,438 |
| 9 | Protagonist Therapeutics | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 10 | ImmunityBio | 2025 | Richard Adcock | 831,667 | 2,787,828 | 8,353,406 | 485,166 | 12,716,953 |
| 11 | Cytokinetics | 2025 | Robert Blum | 853,069 | 5,150,019 | 5,095,918 | 772,715 | 11,881,456 |
| 12 | Apellis Pharmaceuticals | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 13 | Kiniksa Pharmaceuticals | 2025 | Sanj Patel | 943,129 | 3,798,021 | 4,743,446 | 1,284,065 | 10,782,661 |
| 14 | Crispr Therapeutics | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 15 | Syndax Pharmaceuticals | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 16 | Arvinas | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 17 | Celldex Therapeutics, Inc. | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 18 | Denali Therapeutics | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 19 | Inhibrx | 2025 | Mark Lappe | 695,250 | 0 | 0 | 479,723 | 2,892,473 |
| 20 | Keros Therapeutics | 2025 | Jasbir Seehra | 700,000 | 1,426,280 | 0 | 398,125 | 2,540,204 |
| 21 | Zentalis Pharmaceuticals | 2025 | Julie Eastland | 700,000 | 99,772 | 56,975 | 441,000 | 1,300,731 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Celldex Therapeutics, Inc. | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Apellis Pharmaceuticals | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Arcellx | 140% | not disclosed | No | Meridian Compensation Partners |
| Arvinas | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Biohaven | not disclosed | not disclosed | not disclosed | Aon |
| BridgeBio Pharma | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Crispr Therapeutics | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Cytokinetics | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| Denali Therapeutics | 145% | not disclosed | not disclosed | Alpine Rewards |
| ImmunityBio | not disclosed | Option 75 · RSU 25 | not disclosed | Mercer |
| Immunovant | 110% | not disclosed | No | Compensia |
| Inhibrx | not disclosed | Option 100 | not disclosed | not disclosed |
| Keros Therapeutics | 87.5% | RSU 50 · PSU 50 | No | Aon (Human Capital Solutions practice) |
| Kiniksa Pharmaceuticals | not disclosed | Option 50 · RSU 25 · PSU 25 | not disclosed | Compensia, Inc. |
| Madrigal Pharmaceuticals | not disclosed | PSU 33.33 · RSU 33.33 · Option 33.33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia, Inc. |
| Protagonist Therapeutics | 160% | Options 50 · RSU 50 | not disclosed | Aon Human Capital Solutions |
| Roivant Sciences | not disclosed | not disclosed | not disclosed | Aon |
| SpringWorks Therapeutics | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| Syndax Pharmaceuticals | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Vaxcyte | 105% | not disclosed | not disclosed | Pay Governance |
| Zentalis Pharmaceuticals | 105% | not disclosed | not disclosed | Anderson Pay Advisors LLC / Pay Governance LLC |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-25 | 59,258,619 | 945,414 | 479,683 | 98.43% | Passed |
| 2025 | 2025-06-05 | 53,482,418 | 626,666 | 172,134 | 98.84% | Passed |
| 2024 | 2024-06-13 | 54,182,916 | 945,004 | 439,263 | 98.29% | Passed |
| 2023 | 2023-06-15 | 38,667,727 | 981,947 | 114,437 | 97.52% | Passed |
| 2022 | 2022-06-16 | 40,017,356 | 717,052 | 179,987 | 98.24% | Passed |
| 2021 | 2021-06-17 | 25,334,294 | 1,147,440 | 115,253 | 95.67% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-25 | 98.43%a |
| 2025 | 2025-06-05 | 98.84%b |
| 2024 | 2024-06-13 | 98.29%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on Proposal 1.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on Proposal 1.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on Proposal 1.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 23 : 1 |
|---|---|
| CEO total compensation | $5,366,709 |
| Median employee compensation | $235,733 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Harry H. Penner, Jr | Director | 2026-06-25 | A | 26,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Cheryl L. Cohen | Director | 2026-06-25 | A | 26,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2026-06-25 | A | 26,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anthony S. Marucci | Director | 2026-06-25 | A | 375,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tibor Keler | Executive VP & CSO | 2026-06-25 | A | 115,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Crowley | Sr. VP & CPDO | 2026-06-25 | A | 100,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald Pepin | Sr. VP & CBO | 2026-06-25 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Margo Heath-Chiozzi | SVP of Regulatory Affairs | 2026-06-25 | A | 95,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Freddy A. Jimenez | SVP & General Counsel | 2026-06-25 | A | 93,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Cavanaugh | SVP of Corp Affairs & Admin. | 2026-06-25 | A | 95,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sam Martin | SVP and CFO | 2026-06-25 | A | 93,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Diane C. Young | SVP, Chief Medical Officer | 2026-06-25 | A | 57,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Keith L. Brownlie | Director | 2026-06-25 | A | 26,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Herbert J. Conrad | Director | 2026-06-25 | A | 26,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Garry Arthur Neil | Director | 2026-06-25 | A | 26,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James J. Marino | Director | 2026-06-25 | A | 26,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rita Jain | Director | 2026-06-25 | A | 26,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Teri L. Lawver | SVP & Chief Commercial Officer | 2026-06-25 | A | 90,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (69 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Anthony Marucci. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · page 38. As printed: 5,366,709. View filing ↗
- Section 01, Tibor Keler. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · page 38. As printed: 2,115,717. View filing ↗
- Section 01, Elizabeth Crowley. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · page 38. As printed: 1,885,209. View filing ↗
- Section 01, Sam Martin. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · page 38. As printed: 1,827,112. View filing ↗
- Section 01, Margo Heath-Chiozzi. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · page 38. As printed: 1,820,359. View filing ↗
- Section 03, Margo Heath-Chiozzi OPTION. DEF 14A, filed 2026-04-29. Section “DIRECTORS &” · grants of plan-based awards table. View filing ↗
- Section 03, Anthony Marucci OPTION. DEF 14A, filed 2026-04-29. Section “DIRECTORS &” · grants of plan-based awards table. View filing ↗
- Section 03, Tibor Keler OPTION. DEF 14A, filed 2026-04-29. Section “DIRECTORS &” · grants of plan-based awards table. View filing ↗
- Section 03, Elizabeth Crowley OPTION. DEF 14A, filed 2026-04-29. Section “DIRECTORS &” · grants of plan-based awards table. View filing ↗
- Section 03, Sam Martin OPTION. DEF 14A, filed 2026-04-29. Section “DIRECTORS &” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-29. Section “CEO Pay Ratio”. As printed: 23 : 1. View filing ↗
- Section 08, Denice Torres. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 480,451. View filing ↗
- Section 08, Harry H. Penner, Jr. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 296,939. View filing ↗
- Section 08, James J. Marino. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 294,434. View filing ↗
- Section 08, Keith L. Brownlie. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 289,439. View filing ↗
- Section 08, Garry A. Neil, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 284,445. View filing ↗
- Section 08, Cheryl L. Cohen. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 281,948. View filing ↗
- Section 08, Rita I. Jain, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 279,451. View filing ↗
- Section 08, Herbert J. Conrad. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 279,451. View filing ↗
- Section 08, Anthony S. Marucci. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Harry H. Penner, Jr 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cheryl L. Cohen 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Denice Torres 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Anthony S. Marucci 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tibor Keler 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Crowley 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ronald Pepin 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Margo Heath-Chiozzi 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Freddy A. Jimenez 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Cavanaugh 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sam Martin 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Diane C. Young 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith L. Brownlie 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Herbert J. Conrad 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry Arthur Neil 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James J. Marino 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rita Jain 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Teri L. Lawver 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-26. Item 5.07 · say-on-pay result. As reported: 98.43% (votes for as printed: 59,258,619). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-06. Item 5.07 · say-on-pay result. As reported: 98.84% (votes for as printed: 53,482,418). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-14. Item 5.07 · say-on-pay result. As reported: 98.29% (votes for as printed: 54,182,916). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 492,904 + equity 0 + all other 0 = 492,904, summed across the director compensation table rows.
- Roivant Sciences, Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Roivant Sciences's own proxy. As printed: 24,400,210. View filing ↗
- Arcellx, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Arcellx's own proxy. As printed: 21,402,668. View filing ↗
- Immunovant, Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Immunovant's own proxy. As printed: 20,158,767. View filing ↗
- Madrigal Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals's own proxy. As printed: 19,206,341. View filing ↗
- SpringWorks Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics's own proxy. As printed: 16,153,317. View filing ↗
- BridgeBio Pharma, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. View filing ↗
- Vaxcyte, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vaxcyte's own proxy. As printed: 14,458,937. View filing ↗
- Biohaven, Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in Biohaven's own proxy. As printed: 13,500,438. View filing ↗
- Protagonist Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Protagonist Therapeutics's own proxy. As printed: 12,871,506. View filing ↗
- ImmunityBio, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in ImmunityBio's own proxy. As printed: 12,716,953. View filing ↗
- Cytokinetics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Cytokinetics's own proxy. As printed: 11,881,456. View filing ↗
- Apellis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. View filing ↗
- Kiniksa Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Kiniksa Pharmaceuticals's own proxy. As printed: 10,782,661. View filing ↗
- Crispr Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Crispr Therapeutics's own proxy. As printed: 7,678,477. View filing ↗
- Syndax Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals's own proxy. As printed: 7,089,213. View filing ↗
- Arvinas, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas's own proxy. As printed: 6,534,127. View filing ↗
- Celldex Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Celldex Therapeutics, Inc.'s own proxy. As printed: 5,366,709. View filing ↗
- Denali Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. View filing ↗
- Inhibrx, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Inhibrx's own proxy. As printed: 2,892,473. View filing ↗
- Keros Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Keros Therapeutics's own proxy. As printed: 2,540,204. View filing ↗
- Zentalis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Zentalis Pharmaceuticals's own proxy. As printed: 1,300,731. View filing ↗
- Section 10a, Keros Therapeutics reciprocity. DEF 14A. Keros Therapeutics names Celldex Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Immunovant reciprocity. DEF 14A. Immunovant names Celldex Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Protagonist Therapeutics reciprocity. DEF 14A. Protagonist Therapeutics names Celldex Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Zentalis Pharmaceuticals reciprocity. DEF 14A. Zentalis Pharmaceuticals names Celldex Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗